Mainz Biomed (NASDAQ:MYNZ) Short Interest Update

Mainz Biomed (NASDAQ:MYNZ) saw a large growth in short interest in February. As of February 15th, there was short interest totalling 101,700 shares, a growth of 190.6% from the January 31st total of 35,000 shares. Currently, 5.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 203,700 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Mainz Biomed stock. Virtu Financial LLC bought a new position in Mainz Biomed (NASDAQ:MYNZ) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned approximately 0.92% of Mainz Biomed at the end of the most recent reporting period.

Mainz Biomed Price Performance

Shares of MYNZ traded down $0.81 during mid-day trading on Friday, hitting $5.23. The company’s stock had a trading volume of 191,462 shares, compared to its average volume of 243,598. The firm has a 50-day moving average price of $5.38 and a 200 day moving average price of $8.70. The stock has a market capitalization of $10.47 million, a price-to-earnings ratio of -0.08 and a beta of 0.32. Mainz Biomed has a fifty-two week low of $3.65 and a fifty-two week high of $45.60.

Wall Street Analyst Weigh In

MYNZ has been the topic of a number of recent analyst reports. HC Wainwright downgraded shares of Mainz Biomed from a “buy” rating to a “neutral” rating in a research report on Monday, November 25th. Maxim Group initiated coverage on shares of Mainz Biomed in a research note on Friday, February 14th. They issued a “buy” rating and a $14.00 price objective on the stock.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.